EUROLAB
usp-1231-water-for-pharmaceutical-purposes-and-impurity-effects
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

USP <1231>: Water for Pharmaceutical Purposes and Impurity Effects Laboratory Testing Service Provided by Eurolab

USP <1231> is a widely recognized standard governing the testing of water for pharmaceutical purposes, specifically focusing on impurity effects. The standard is developed and published by the United States Pharmacopeia (USP), an independent scientific organization that sets standards for the quality of ingredients used in medicines and other healthcare products.

Relevant Standards

The USP <1231> standard is based on various international and national standards, including:

  • ISO 3696:2005, Water for analytical laboratory use Specification and test methods

  • ASTM D1193-15, Standard Guide for the Examination of Water Samples by Techniques Other Than Spectroscopy

  • EN 1484:2012, Quality management systems. Requirements for organizations providing audit or certification services

    • Standard Development Organizations

    The USP <1231> standard is developed and maintained by the USPs Expert Committee on Analytical Chemistry (ECAC), which is responsible for developing standards related to analytical chemistry, including water testing.

    International and National Standards

    The USP <1231> standard is part of a broader set of international and national standards that govern water quality testing. Some of these standards include:

  • ISO 3696:2005

  • ASTM D1193-15

  • EN 1484:2012

  • TSE (Turkish Standards Institution) TS 1218:2020, Water for pharmaceutical use Specifications

    • Standard Compliance Requirements

    Compliance with the USP <1231> standard is required by regulatory agencies and industry stakeholders to ensure the quality of water used in pharmaceutical manufacturing. Failure to comply with this standard can result in serious consequences, including product recalls, financial losses, and damage to reputation.

    Standard Evolution and Updates

    Standards evolve over time to reflect advances in technology, changes in regulatory requirements, or new research findings. The USP <1231> standard is updated periodically to ensure it remains relevant and effective in protecting public health.

    Specific Standard Numbers and Scope

    The current version of the USP <1231> standard (2022) includes several key updates, including:

  • New test methods for detecting impurities

  • Revised requirements for water quality parameters

  • Increased emphasis on testing for emerging contaminants

    • Industry-Specific Compliance Requirements

    Compliance with the USP <1231> standard is required by various industries, including:

  • Pharmaceutical manufacturing

  • Biotechnology

  • Cosmetics and personal care products

  • Food processing and packaging

    • Business and Technical Reasons for Conducting USP <1231>: Water for Pharmaceutical Purposes and Impurity Effects Testing

    The USP <1231> standard is necessary due to the potential risks associated with contaminated water, including:

  • Product contamination

  • Patient safety concerns

  • Regulatory non-compliance

  • Financial losses

    • Consequences of Not Performing This Test

    Failure to conduct USP <1231> testing can result in serious consequences, including:

  • Product recalls and withdrawals

  • Loss of customer confidence and trust

  • Reputation damage and financial losses

  • Non-compliance with regulatory requirements

    • Industries and Sectors Requiring This Testing

    The following industries and sectors require USP <1231> testing to ensure water quality:

  • Pharmaceutical manufacturing

  • Biotechnology

  • Cosmetics and personal care products

  • Food processing and packaging

  • Water treatment and purification services

    • Risk Factors and Safety Implications

    Contaminated water can have serious safety implications, including:

  • Product contamination

  • Patient safety concerns

  • Environmental pollution

  • Economic losses

    • Quality Assurance and Quality Control Aspects

    Eurolabs USP <1231> testing service ensures compliance with quality assurance and quality control requirements, including:

  • Strict sampling protocols

  • Accurate and precise testing methods

  • Regular calibration and validation procedures

  • Documented records and reporting

    • Competitive Advantages of Having This Testing Performed

    By conducting USP <1231> testing, companies can:

  • Enhance product safety and reliability

  • Improve regulatory compliance

  • Increase customer confidence and trust

  • Reduce the risk of product contamination and recalls

  • Gain a competitive edge in the market

    • Cost-Benefit Analysis of Performing This Test

    The cost-benefit analysis of performing USP <1231> testing is clear:

  • Compliance with regulatory requirements

  • Protection of patient safety and public health

  • Reduced risk of product contamination and recalls

  • Improved reputation and customer confidence

  • Cost savings through reduced recall and replacement costs

    • The USP <1231> standard requires laboratory testing to be conducted under specific conditions, including:

  • Temperature: 20C 2C

  • Humidity: 50 5

  • Lighting: Protected from direct sunlight

    • Sampling Protocols

    Sampling protocols for USP <1231> testing include:

  • Selecting representative samples

  • Handling and storing samples properly

  • Ensuring sample integrity and authenticity

    • Testing Methods

    USP <1231> testing involves a range of methods, including:

  • Spectrophotometry

  • Chromatography (HPLC and GC)

  • Mass spectrometry (MS)

    • Calibration and Validation Procedures

    Eurolabs USP <1231> testing service ensures that all equipment is calibrated and validated regularly to ensure accuracy and precision.

    Documented Records and Reporting

    All test results are documented and reported in accordance with regulatory requirements, including:

  • Standard operating procedures (SOPs)

  • Quality control records

  • Test reports

    • Persuasive Conclusion

    In conclusion, the USP <1231> standard is a critical requirement for ensuring water quality in pharmaceutical manufacturing. By conducting USP <1231> testing, companies can enhance product safety and reliability, improve regulatory compliance, increase customer confidence and trust, reduce the risk of product contamination and recalls, and gain a competitive edge in the market.

    Recommendation

    We recommend that all pharmaceutical manufacturers conduct regular USP <1231> testing to ensure compliance with regulatory requirements and protect public health.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers